Clinical Trial Update: to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating preliminary efficacy and safety of GR1501 Injection for active axial spondyloarthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis

Drugs mentioned

• GR1501 Injection

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Axial Spondyloarthritis | Phase 2 | Status: COMPLETED